Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
Labcorp Holdings Inc. reported that its President, CEO and director Adam H. Schechter received new equity awards on February 10, 2026. He was granted 31,700 non-qualified stock options with a $284.50 exercise price, vesting in three equal annual installments and expiring in 2036.
He also received 10,440 Restricted Stock Units (RSUs), each representing one share of Labcorp common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this grant, he holds an aggregate of 25,870 RSUs.
Labcorp Holdings Inc. executive Jonathan C. Meltzer reported multiple equity transactions. On February 10, 2026, he sold 91 shares of Labcorp common stock in an open-market transaction at $276.79 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 2,696.3256 shares held directly.
On the same date, he was granted 1,900 non-qualified stock options with an exercise price of $284.50, vesting in three equal annual installments starting February 10, 2027 and expiring on February 9, 2036. He also received 620 restricted stock units, which vest in three equal annual installments beginning February 10, 2027, bringing his directly held RSUs to 2,937 units, each representing one share of Labcorp common stock.
Labcorp Holdings Inc. executive Kathryn W. Kyle, EVP and Chief Legal Officer, reported new equity awards. On February 10, 2026, she received 2,700 non-qualified stock options with an exercise price of
She was also granted 880 Restricted Stock Units (RSUs), each representing one share of common stock. The RSUs vest in three equal annual installments beginning on
Labcorp Holdings Inc. executive Bryan T. Vaughn reported equity awards granted on February 10, 2026. He received non-qualified stock options on 2,200 shares of common stock at an exercise price of
He was also granted 730 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this RSU grant, Vaughn directly holds 4,354 Restricted Stock Units in total.
Labcorp Holdings Inc. chief financial officer Julia Aijun Wang received new equity awards. On February 10, 2026, she was granted 7,100 non-qualified stock options with an exercise price of $284.50 per share and 2,350 restricted stock units.
The options vest in three equal annual installments starting on the grant date and are exercisable until February 9, 2036. The restricted stock units also vest in three equal annual installments beginning on February 10, 2027, with each unit delivering one share of Labcorp common stock.
Labcorp Holdings Inc. reported that SVP and Chief Accounting Officer Peter J. Wilkinson acquired new equity awards on February 10, 2026. He received non-qualified stock options for 1,300 shares of common stock with an exercise price of $284.5 per share, granted under the 2025 Omnibus Incentive Plan. These options vest in three equal annual installments starting on that grant date and expire on February 9, 2036.
Wilkinson was also granted 440 Restricted Stock Units, each representing one share of common stock, vesting in three equal annual installments beginning on February 10, 2027. Following this grant, he holds 2,664 Restricted Stock Units in total, all reported as directly owned.
Labcorp Holdings Inc. executive Akinbolade Oyegunwa reported new equity awards. On 02/10/2026, the EVP, CIO & CTO acquired 2,400 non-qualified stock options with an exercise price of $284.5 per share under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.
The options vest in three equal annual installments beginning on 02/10/2026 and are exercisable until 02/09/2036. On the same date, Oyegunwa also received 810 Restricted Stock Units, each representing one share of common stock, which will vest in three equal annual installments beginning on February 10, 2027. Following this grant, Oyegunwa holds 2,420 Restricted Stock Units in total.
Labcorp Holdings Inc. executive Amy B. Summy, EVP and Chief Marketing Officer, reported new equity awards on February 10, 2026. She received 1,900 non-qualified stock options with an exercise price of $284.50 per share under the 2025 Omnibus Incentive Plan. These options vest in three equal annual installments starting on the grant date and cover 1,900 shares of common stock.
She also acquired 620 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this grant, she directly holds 1,534 RSUs in total. The filing reflects routine compensation-related awards rather than open-market purchases or sales.
Labcorp Holdings Inc. executive Anita Z. Graham, EVP and Chief Human Resources Officer, reported equity awards granted on February 10, 2026. She received non-qualified stock options for 4,100 shares of common stock with an exercise price of $284.5 per share, vesting in three equal annual installments beginning that date. She was also granted 1,360 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this award, she holds 2,757 Restricted Stock Units in total.
Labcorp Holdings Inc. executive Megan D. Bailey reported equity awards received on February 10, 2026. She was granted 3,300 non-qualified stock options with a $284.5 exercise price under the 2025 Omnibus Incentive Plan, vesting in three equal annual installments starting on that grant date.
She was also granted 1,100 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. After this grant, she directly holds 3,300 stock options and 3,230 Restricted Stock Units.